Asia Pacific Prostate Cancer Diagnostic and Therapeutic Market to Reach $14,951.9 Million by 2035

Asia Pacific prostate cancer diagnostic and therapeutic market was valued at $5,914.1 million in 2025 and is projected to reach $14,951.9 million by 2035, growing at a CAGR of 9.8% during the forecast period (2026–2035). Japan, Australia and other Asia Pacific governments are reporting rising prostate cancer burdens that are changing clinical priorities and purchasing behavior. For instance, Japan’s National Cancer Center projects prostate cancer among the largest site-specific burdens nationally roughly 99,900 prostate cancer cases in 2024. These government-level trends act as a direct market driver. When national experts and professional bodies (APCCC-style consensus forums) converge on practice patterns that lowers clinical uncertainty and accelerates procurement of advanced imaging (PSMA PET), digital pathology plus explainable AI, molecular diagnostics and next-generation therapeutics. Policy makers and hospital systems respond to clear national burden data by prioritizing screening programs, reimbursement reviews and capacity upgrades each action expands addressable demand for diagnostic consumables, imaging radiotracers, pathology software, and therapeutic agents across the Asia Pacific market.

Browse the full report description of “Asia-Pacific Prostate Cancer Diagnostic and Therapeutic Market Size, Share & Trends Analysis Report by Diagnostic Technique (Prostate-Specific Antigen Test, Digital Rectal Examination, Prostate Biopsy, Imaging Techniques) by Therapeutics (Hormonal Therapy, Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy, Surgery) Forecast Period, (2026-2035)” at https://www.omrglobal.com/industry-reports/asia-pacific-prostate-cancer-diagnostic-therapeutic-market

Key Leaders Transforming the Asia Pacific Prostate Cancer Diagnostic and Therapeutic Market

The key players in the Asia Pacific prostate cancer diagnostic and therapeutic market include F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, among others. Companies operating in the Asia Pacific prostate cancer diagnostic and therapeutic market are advancing innovation through enhanced molecular testing, precision imaging technologies, and next-generation targeted therapies. Continued investment in biomarker research, radioligand treatments, and minimally invasive surgical systems is improving diagnostic accuracy and clinical outcomes.

• In June 2025, Sinotau Pharmaceuticals Group, an innovative radiopharmaceuticals company headquartered in Beijing, China, with global reach, announced the initiation of a phase 3 study for prostate cancer prostate specific membrane antigen (PSMA) positron emission tomography (PET) diagnostic imaging agent, flotufolastat (18F) injection.  Sinotau has licensed this product from Blue Earth Diagnostics, a Bracco company and recognised leader in the development and commercialisation of innovative PET radiopharmaceuticals.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Diagnostic Technique
  • By Therapeutics
• Competitive Landscape - F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., Johnson & Johnson, AstraZeneca plc, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Asia Pacific Prostate Cancer Diagnostic and Therapeutic Market Report Segment

By Diagnostic Technique

• Prostate-Specific Antigen Test
• Digital Rectal Examination
• Prostate Biopsy
• Imaging Techniques

By Therapeutics

• Hormonal Therapy
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Targeted Therapy
• Surgery

Asia Pacific Prostate Cancer Diagnostic and Therapeutic Market Report Segment by Country

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, and Others)
• Rest of Asia-Pacific

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/asia-pacific-prostate-cancer-diagnostic-therapeutic-market